User:Mr. Ibrahem/Ceftazidime/avibactam

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ceftazidime/avibactam
Combination of
CeftazidimeCephalosporin antibiotic
Avibactamβ-lactamase inhibitor
Clinical data
Trade namesAvycaz, Zavicefta, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa615018
License data
Routes of
administration		Intravenous infusion
Drug classAntibiotic
Legal status
Legal status
 ☒NcheckY (what is this?)

Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor.[2] It is used to treat complicated intra abdominal infections, urinary tract infections, and pneumonia.[2][3] It is only recommended when other options are not appropriate.[2] It is given by injection into a vein.[2]

Common side effect include nausea, fever, liver problems, headache, trouble sleeping, and pain at the site of injection.[2] Severe side effects may include anaphylaxis, seizures, and Clostridium difficile-associated diarrhea.[2] While use appears to be safe in pregnancy the medication has not been well studied in this group.[5] Doses should be adjusted in those with kidney problems.[6] Ceftazidime works by interfering with the building of the bacterial cell wall while avibactam works by preventing ceftazidime's breakdown.[2]

The combination was approved for medical use in the United States and Europe in 2015.[2][3] It is on the World Health Organization's List of Essential Medicines.[7] In the United States a course of treatment generally costs between US$7,500 to US$15,000 as of 2016.[6] In the United Kingdom this amount costs the NHS about £1,800 to £3,600 as of 2019.[8]

References[edit]

  1. ^ "Briefing package: ceftazidime-avibactam. Anti-infective drugs advisory committee meeting" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 30 June 2015. Retrieved 27 June 2015.
  2. ^ a b c d e f g h i j "Ceftazidime and Avibactam Sodium Monograph for Professionals". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
  3. ^ a b c "Application for inclusion of ceftazidime-avibactam" (PDF). WHO. Archived (PDF) from the original on 28 August 2021. Retrieved 25 October 2019.
  4. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 11 September 2020.
  5. ^ "Avibactam / ceftazidime (Avycaz) Use During Pregnancy". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
  6. ^ a b Mosley JF, 2nd; Smith, LL; Parke, CK; Brown, JA; Wilson, AL; Gibbs, LV (August 2016). "Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections". Pharmacy and Therapeutics. 41 (8): 479–83. PMC 4959616. PMID 27504064.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. X. ISBN 9780857113382.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ceftazidime/avibactam&oldid=1117223954"